Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis. - Archive ouverte HAL Access content directly
Journal Articles Current Medicinal Chemistry Year : 2013

Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis.

(1) , (1) , (2) , (1)
1
2

Abstract

The trypanosomatids Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp. cause Chagas disease, leishmaniasis and human African trypanosomiasis, respectively. It is estimated that over 10 million people worldwide suffer from these neglected diseases, posing enormous social and economic problems in endemic areas. There are no vaccines to prevent these infections and chemotherapies are not adequate. This picture indicates that new chemotherapeutic agents must be developed to treat these illnesses. For this purpose, understanding the biology of the pathogenic trypano-somatid-host cell interface is fundamental for molecular and functional characterization of virulence factors that may be used as targets for the development of inhibitors to be used for effective chemotherapy. In this context, it is well known that proteases have crucial functions for both metabolism and infectivity of pathogens and are thus potential drug targets. In this regard, prolyl oligopeptidase and oligopeptidase B, both members of the S9 serine protease family, have been shown to play important roles in the interactions of pathogenic protozoa with their mammalian hosts and may thus be considered targets for drug design. This review aims to discuss structural and functional properties of these intriguing enzymes and their potential as targets for the development of drugs against Chagas disease, leishmaniasis and African try-panosomiasis.

Dates and versions

mnhn-02070064 , version 1 (20-12-2022)

Identifiers

Cite

Izabela M. D. Bastos, Flávia Nader N Motta, Philippe Grellier, Jaime Martins Santana. Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis.. Current Medicinal Chemistry, 2013, 20 (25), pp.3103-3115. ⟨10.2174/0929867311320250006⟩. ⟨mnhn-02070064⟩

Collections

MNHN CNRS
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More